Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Citations
2,086 citations
1,695 citations
1,403 citations
Cites background from "Axicabtagene Ciloleucel CAR T-Cell ..."
...Two CD19 CAR T cell products were recently approved in the United States and Europe [1-4], andmore indications are expected in the coming years....
[...]
...Two CAR T products were recently approved in the United States and Europe for the treatment of patients up to age 25 years with relapsed or refractory B cell acute lymphoblastic leukemia and/or adults with large B cell lymphoma....
[...]
...In addition, refractory HLH/MAS has been described only in rare cases of immune effector cellassociated CRS [2,28], whereas in the vast majority of patients, the symptoms (and characteristic elevated cytokines) suggestive of HLH/MAS resolve with CRS resolution [22]....
[...]
...Although prospective clinical trials evaluating the timing of intervention are lacking, retrospective analyses suggest that this is not the case, at least when such therapies are implemented after CRS is well under way [2,21]....
[...]
...Several reports suggest a role for proinflammatory cytokines and myeloid cells besides activated T cells [2,18,29,3133]....
[...]
1,302 citations
1,295 citations
References
13,835 citations
4,208 citations
Additional excerpts
...Any 94 (93) 81 (80) 13 (13) Pyrexia 77 (76) 66 (65) 11 (11) Hypotension 41 (41) 32 (32) 9 (9) Hypoxia 22 (22) 13 (13) 9 (9) Tachycardia 21 (21) 20 (20) 1 (1) Chills 20 (20) 20 (20) 0 Sinus tachycardia 8 (8) 8 (8) 0 Headache 5 (5) 5 (5) 0 Table 2....
[...]
4,080 citations
2,257 citations
Additional excerpts
...(%)‖ Negative 7/63 (11) 1/19 (5) 8/82 (10) Positive 56/63 (89) 18/19 (95) 74/82 (90) Prior therapies — no....
[...]
2,064 citations